pamidronate has been researched along with Hypocalcemia in 35 studies
Hypocalcemia: Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is a case report of a patient who developed severe, irreversible hypocalcemia after receiving one dose of pamidronate 90 mg for hypercalcemia of malignancy." | 7.91 | A case of severe, irreversible hypocalcemia after one dose of pamidronate administered for hypercalcemia of malignancy. ( Kim, S, 2019) |
| "The six patients, who had bone fractures either in utero or in their 1st month of life, were treated with cyclic pamidronate from a mean age of 2." | 7.80 | Cyclic pamidronate infusion for neonatal-onset osteogenesis imperfecta. ( Chien, CC; Chien, YH; Hwu, WL; Lee, CT; Lee, NC; Lin, CH; Peng, SF; Tsai, WY; Tung, YC, 2014) |
| "The purpose of this study is to evaluate the acute effect of pamidronate on plasma ionized calcium (iCa) level reduction and dynamic parathyroid hormone (PTH) secretion in postmenopausal hemodialysis-dependent women with secondary hyperparathyroidism." | 7.72 | Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. ( Chu, P; Lin, SH; Lin, YF; Lu, KC; Yeung, LK, 2003) |
| "A 62-yr-old woman with thyroid carcinoma metastatic to bone, and a history of subclinical hypoparathyroidism was admitted to the hospital in hypocalcemic crisis 5 wk after receiving iv pamidronate." | 7.71 | Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. ( Jonklaas, J; Mishra, A; Wong, L, 2001) |
| "A 65-year-old woman admitted for palliative care of metastatic renal/bladder carcinoma developed symptomatic hypocalcemia nine days following a single dose of pamidronate." | 7.69 | Symptomatic hypocalcemia after intravenous pamidronate. ( Bruera, E; McIntyre, E, 1996) |
| "Hypocalcemia is a potential adverse effect of these drugs, which is considered infrequent and rarely symptomatic." | 5.32 | Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports. ( Basuyau, JP; Brunelle, P; Champallou, C; Chevrier, A; Chinet, P; Debled, M; Grongnet, MH; Veyret, C, 2003) |
| "Pamidronate is an effective drug used not only in patients with tumor-associated hypercalcemia, but also in normocalcemic patients with metastatic bone disease to relieve pains." | 5.30 | Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate. ( Alakavuklar, M; Biberoglu, S; Cömlekçi, A; Hekimsoy, Z; Okan, I; Pişkin, O; Sekeroglu, B, 1998) |
| "This is a case report of a patient who developed severe, irreversible hypocalcemia after receiving one dose of pamidronate 90 mg for hypercalcemia of malignancy." | 3.91 | A case of severe, irreversible hypocalcemia after one dose of pamidronate administered for hypercalcemia of malignancy. ( Kim, S, 2019) |
| " Calciphylaxis process started when she received calcium gluconate intravenously the day before the surgery to correct hypocalcemia and continued progressively despite peritoneal dialysis and forced stopping calcium-containing medication." | 3.81 | Successful treatment of calciphylaxis with pamidronate. ( Hooman, N; Jahangiri, F; Mehrazma, M; Naghshi-Zadiyan, R, 2015) |
| "The six patients, who had bone fractures either in utero or in their 1st month of life, were treated with cyclic pamidronate from a mean age of 2." | 3.80 | Cyclic pamidronate infusion for neonatal-onset osteogenesis imperfecta. ( Chien, CC; Chien, YH; Hwu, WL; Lee, CT; Lee, NC; Lin, CH; Peng, SF; Tsai, WY; Tung, YC, 2014) |
| "The purpose of this study is to evaluate the acute effect of pamidronate on plasma ionized calcium (iCa) level reduction and dynamic parathyroid hormone (PTH) secretion in postmenopausal hemodialysis-dependent women with secondary hyperparathyroidism." | 3.72 | Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. ( Chu, P; Lin, SH; Lin, YF; Lu, KC; Yeung, LK, 2003) |
| "The pregnancies of two women with osteogenesis imperfecta who received intravenous pamidronate before conception are reported." | 3.72 | Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. ( Glorieux, FH; Munns, CF; Rauch, F; Ward, L, 2004) |
| "A 62-yr-old woman with thyroid carcinoma metastatic to bone, and a history of subclinical hypoparathyroidism was admitted to the hospital in hypocalcemic crisis 5 wk after receiving iv pamidronate." | 3.71 | Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. ( Jonklaas, J; Mishra, A; Wong, L, 2001) |
| "A 65-year-old woman admitted for palliative care of metastatic renal/bladder carcinoma developed symptomatic hypocalcemia nine days following a single dose of pamidronate." | 3.69 | Symptomatic hypocalcemia after intravenous pamidronate. ( Bruera, E; McIntyre, E, 1996) |
| "Hypocalcemia was treated with calcium and vitamin D3 supplements." | 2.44 | [Zoledronate-associated end stage renal failure and hypocalcaemia]. ( Bodmer, M; Kummer, O; Ramazzina, C; Rätz Bravo, AE; Zysset Aschmann, Y, 2007) |
| "Primary hyperparathyroidism is characterized by hypercalcemia with loss of bone mass." | 1.33 | Bisphosphonate pretreatment attenuates hungry bone syndrome postoperatively in subjects with primary hyperparathyroidism. ( Kuo, SW; Lee, IT; Pei, D; Sheu, WH; Tu, ST, 2006) |
| "Hypocalcemia is a potential adverse effect of these drugs, which is considered infrequent and rarely symptomatic." | 1.32 | Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports. ( Basuyau, JP; Brunelle, P; Champallou, C; Chevrier, A; Chinet, P; Debled, M; Grongnet, MH; Veyret, C, 2003) |
| "Pamidronate is an effective drug used not only in patients with tumor-associated hypercalcemia, but also in normocalcemic patients with metastatic bone disease to relieve pains." | 1.30 | Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate. ( Alakavuklar, M; Biberoglu, S; Cömlekçi, A; Hekimsoy, Z; Okan, I; Pişkin, O; Sekeroglu, B, 1998) |
| " In osteoporotic syndromes, APD is prescribed at a lower dosage (200 mg/day) and currently calcium or vitamin D are also systematically added." | 1.29 | [Effect of low doses of oral pamidronate (APD) on the calcemia of osteopenic or osteoporotic patients]. ( Castelli, G; Kerzberg, EM; Lloret, AP; Roldan, EJ, 1996) |
| "There were seven patients with breast cancer, eight with lung cancer, and ten with a variety of other cancers." | 1.28 | Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia. ( Cantwell, BM; Carmichael, J; Harris, AL; Mannix, KA, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (8.57) | 18.7374 |
| 1990's | 12 (34.29) | 18.2507 |
| 2000's | 14 (40.00) | 29.6817 |
| 2010's | 6 (17.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, N | 1 |
| Reilly, RF | 1 |
| Kim, S | 1 |
| Boumans, D | 1 |
| de Vries, PA | 1 |
| Rikken, NE | 1 |
| Laverman, GD | 1 |
| Lin, CH | 1 |
| Chien, YH | 1 |
| Peng, SF | 1 |
| Tsai, WY | 1 |
| Tung, YC | 1 |
| Lee, CT | 1 |
| Chien, CC | 1 |
| Hwu, WL | 1 |
| Lee, NC | 1 |
| McKay, RR | 1 |
| Lin, X | 1 |
| Perkins, JJ | 1 |
| Heng, DY | 1 |
| Simantov, R | 1 |
| Choueiri, TK | 1 |
| Hooman, N | 1 |
| Naghshi-Zadiyan, R | 1 |
| Mehrazma, M | 1 |
| Jahangiri, F | 1 |
| Singh, R | 1 |
| Menon, Y | 1 |
| Cuchacovich, R | 1 |
| Espinoza, LR | 1 |
| Champallou, C | 1 |
| Basuyau, JP | 1 |
| Veyret, C | 1 |
| Chinet, P | 1 |
| Debled, M | 1 |
| Chevrier, A | 1 |
| Grongnet, MH | 1 |
| Brunelle, P | 1 |
| Rosen, CJ | 1 |
| Brown, S | 1 |
| Lu, KC | 1 |
| Yeung, LK | 1 |
| Lin, SH | 1 |
| Lin, YF | 1 |
| Chu, P | 1 |
| Altundag, O | 1 |
| Altundag, K | 1 |
| Munns, CF | 1 |
| Rauch, F | 1 |
| Ward, L | 1 |
| Glorieux, FH | 1 |
| Tralongo, P | 1 |
| Repetto, L | 1 |
| Di Mari, A | 1 |
| Mauceri, G | 1 |
| Bollina, R | 1 |
| Ferrau', F | 1 |
| Conti, G | 1 |
| Henley, D | 1 |
| Kaye, J | 1 |
| Walsh, J | 1 |
| Cull, G | 1 |
| Lee, IT | 1 |
| Sheu, WH | 1 |
| Tu, ST | 1 |
| Kuo, SW | 1 |
| Pei, D | 1 |
| Ramazzina, C | 1 |
| Zysset Aschmann, Y | 1 |
| Kummer, O | 1 |
| Rätz Bravo, AE | 1 |
| Bodmer, M | 1 |
| Davenport, A | 1 |
| Stearns, MP | 1 |
| Gurevich, Y | 1 |
| Poretsky, L | 1 |
| Adami, S | 1 |
| Frijlink, WB | 1 |
| Bijvoet, OL | 1 |
| O'Riordan, JL | 1 |
| Clemens, TL | 1 |
| Papapoulos, SE | 2 |
| Landman, JO | 1 |
| Schweitzer, DH | 1 |
| Frölich, M | 1 |
| Hamdy, NA | 1 |
| Purohit, OP | 1 |
| Anthony, C | 1 |
| Radstone, CR | 1 |
| Owen, J | 1 |
| Coleman, RE | 1 |
| Varma, N | 1 |
| Kerrigan, GN | 1 |
| McIntyre, E | 1 |
| Bruera, E | 1 |
| Roldan, EJ | 1 |
| Kerzberg, EM | 1 |
| Castelli, G | 1 |
| Lloret, AP | 1 |
| Kutluk, T | 1 |
| Akyüz, C | 1 |
| Yalçin, B | 1 |
| Varan, A | 1 |
| Büyükpamuküçu, M | 1 |
| Cömlekçi, A | 1 |
| Biberoglu, S | 1 |
| Hekimsoy, Z | 1 |
| Okan, I | 1 |
| Pişkin, O | 1 |
| Sekeroglu, B | 1 |
| Alakavuklar, M | 1 |
| Sims, EC | 1 |
| Rogers, PB | 1 |
| Besser, GM | 1 |
| Plowman, PN | 1 |
| Chong, G | 1 |
| Hoang, T | 1 |
| Davis, ID | 1 |
| De Schepper, J | 1 |
| de Pont, S | 1 |
| Smitz, J | 1 |
| De Coster, D | 1 |
| Schots, R | 1 |
| Otten, J | 1 |
| Malberti, F | 1 |
| Farina, M | 1 |
| Imbasciati, E | 1 |
| Mishra, A | 1 |
| Wong, L | 1 |
| Jonklaas, J | 1 |
| Stuckey, BG | 1 |
| Lim, EM | 1 |
| Kent, GN | 1 |
| Ward, LC | 1 |
| Gutteridge, DH | 1 |
| Body, JJ | 1 |
| Mannix, KA | 1 |
| Carmichael, J | 1 |
| Harris, AL | 1 |
| Cantwell, BM | 1 |
| Jodrell, DI | 1 |
| Iveson, TJ | 1 |
| Smith, IE | 1 |
3 reviews available for pamidronate and Hypocalcemia
| Article | Year |
|---|---|
Hungry bone syndrome.
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; Calcium; Diphosphonates; Hum | 2017 |
[Zoledronate-associated end stage renal failure and hypocalcaemia].
Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; | 2007 |
Bone metastases and tumor-induced hypercalcemia.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Calcitonin; Combined Modality Therapy; Dipho | 1992 |
2 trials available for pamidronate and Hypocalcemia
| Article | Year |
|---|---|
Recovery of serum calcium concentrations following acute hypocalcemia in patients with osteoporosis on long-term oral therapy with the bisphosphonate pamidronate.
Topics: Acute Disease; Administration, Oral; Aged; Calcium; Diphosphonates; Edetic Acid; Female; Humans; Hyp | 1995 |
High-dose intravenous pamidronate for metastatic bone pain.
Topics: Bone and Bones; Bone Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Hy | 1994 |
30 other studies available for pamidronate and Hypocalcemia
| Article | Year |
|---|---|
A case of severe, irreversible hypocalcemia after one dose of pamidronate administered for hypercalcemia of malignancy.
Topics: Bone Neoplasms; Calcium; Humans; Hypercalcemia; Hypocalcemia; Male; Middle Aged; Pamidronate; Risk F | 2019 |
Prolonged hypocalcaemia after pamidronate infusion in Riedel's thyroiditis associated hypoparathyroidism.
Topics: Bone Density Conservation Agents; Calcium Carbonate; Dihydrotachysterol; Diphosphonates; Female; Gas | 2013 |
Cyclic pamidronate infusion for neonatal-onset osteogenesis imperfecta.
Topics: Bone Density; Child; Child, Preschool; Diphosphonates; Drug Administration Schedule; Female; Fractur | 2014 |
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Dens | 2014 |
Successful treatment of calciphylaxis with pamidronate.
Topics: Biopsy; Calciphylaxis; Calcium Gluconate; Debridement; Diphosphonates; Female; Humans; Hypocalcemia; | 2015 |
A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis: comment on the article by Maksymowych et a
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Diphosphonates; Double-Bli | 2003 |
Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Hypocalcemia; Male; Middle Ag | 2003 |
Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency.
Topics: Diphosphonates; Female; Gastroplasty; Humans; Hypocalcemia; Infusions, Intravenous; Malabsorption Sy | 2003 |
Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
Topics: Aged; Chronic Kidney Disease-Mineral and Bone Disorder; Diphosphonates; Female; Humans; Hypercalcemi | 2003 |
Pamidronate, hypocalcemia, and calcium and vitamin D supplementation.
Topics: Bone Neoplasms; Confounding Factors, Epidemiologic; Diphosphonates; Humans; Hypocalcemia; Male; Pami | 2004 |
Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases.
Topics: Adult; Anti-Inflammatory Agents; Clubfoot; Diphosphonates; Female; Humans; Hypocalcemia; Infant; Inj | 2004 |
Safety of long-term administration of bisphosphonates in elderly cancer patients.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration S | 2004 |
Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.
Topics: Acute Kidney Injury; Aged; Bone Density Conservation Agents; Calcitriol; Calcium Carbonate; Diphosph | 2005 |
Bisphosphonate pretreatment attenuates hungry bone syndrome postoperatively in subjects with primary hyperparathyroidism.
Topics: Adult; Aged; Calcium; Clodronic Acid; Diphosphonates; Female; Humans; Hyperparathyroidism, Primary; | 2006 |
Administration of pamidronate helps prevent immediate postparathyroidectomy hungry bone syndrome.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Hypocalcemia; Male; Middle Aged; P | 2007 |
Possible prevention of hungry bone syndrome following parathyroidectomy by preoperative use of pamidronate.
Topics: Adenoma; Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Hypocalcemia; Pamid | 2008 |
Regulation of calcium absorption by 1,25,dihydroxy-vitamin D--studies of the effects of a bisphosphonate treatment.
Topics: Aged; Bone Resorption; Calcitriol; Calcium; Diphosphonates; Humans; Hypocalcemia; Middle Aged; Ostei | 1982 |
Electrocardiographic Q-Tc prolongation associated with infusion of intravenous pamidronate disodium.
Topics: Aged; Arrhythmias, Cardiac; Diphosphonates; Electrocardiography; Female; Humans; Hypocalcemia; Infus | 1993 |
Symptomatic hypocalcemia after intravenous pamidronate.
Topics: Aged; Alberta; Carcinoma, Transitional Cell; Diphosphonates; Female; Humans; Hypercalcemia; Hypocalc | 1996 |
[Effect of low doses of oral pamidronate (APD) on the calcemia of osteopenic or osteoporotic patients].
Topics: Administration, Oral; Analysis of Variance; Bone Diseases, Metabolic; Bone Resorption; Calcium, Diet | 1996 |
Use of pamidronate in the management of acute cancer-related hypercalcemia in children.
Topics: Antineoplastic Agents; Child; Diphosphonates; Humans; Hypercalcemia; Hypocalcemia; Hypophosphatemia; | 1998 |
Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Carcinoma; Diphosphonates; | 1998 |
Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia.
Topics: Adenocarcinoma; Adenoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 1998 |
Symptomatic hypocalcaemia following intravenous pamidronate in cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Diphosphonates; Female; Humans; Hypocalcemia; Infusi | 1999 |
Metabolic disturbances after a single dose of 30 mg pamidronate for leukaemia-associated hypercalcaemia in a 11-year-old boy.
Topics: Antineoplastic Agents; Calcium; Child; Diphosphonates; Humans; Hypercalcemia; Hypocalcemia; Leukemia | 1999 |
The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism.
Topics: Calcium; Diphosphonates; Humans; Hyperparathyroidism; Hypocalcemia; Ions; Osmolar Concentration; Pam | 1999 |
Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism.
Topics: Antineoplastic Agents; Bone Neoplasms; Calcitonin; Calcium Carbonate; Diphosphonates; Female; Humans | 2001 |
Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
Topics: Alendronate; Calcitriol; Calcium; Cervical Vertebrae; Diphosphonates; Female; Humans; Hypocalcemia; | 2001 |
Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia.
Topics: Adult; Aged; Diphosphonates; Female; Follow-Up Studies; Humans; Hypercalcemia; Hypocalcemia; Infusio | 1989 |
Symptomatic hypocalcaemia after treatment with high-dose aminohydroxypropylidene diphosphonate.
Topics: Diphosphonates; Female; Humans; Hypercalcemia; Hypocalcemia; Middle Aged; Pamidronate | 1987 |